German company begins human trial of Covid-19 vaccine
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
TUESDAY, MAY 24, 2022
TUESDAY, MAY 24, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
German company begins human trial of Covid-19 vaccine

Coronavirus chronicle

TBS Report
30 April, 2020, 02:00 pm
Last modified: 30 April, 2020, 03:32 pm

Related News

  • Covax calls for urgent action to close vaccine equity gap
  • Over 700,000 refugees from Ukraine registered in Germany -Welt
  • Cholera inoculation in Dhaka starting first week of May
  • Corruption allegation over vaccine has no evidence: Ahmad Kaikaus
  • 23 lakh citizens to get cholera vaccine in Dhaka from May

German company begins human trial of Covid-19 vaccine

BioNTech in collaboration with the US-based Pfizer announced that 12 participants of a clinical trial in Germany received doses of the vaccine candidate BNT162

TBS Report
30 April, 2020, 02:00 pm
Last modified: 30 April, 2020, 03:32 pm
Small bottles labbeled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken taken April 10, 2020/ Reuters
Small bottles labbeled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken taken April 10, 2020/ Reuters

BioNTech, a German pharmaceutical company has begun testing a potential vaccine for the new coronavirus on patients who are approaching voluntarily.

BioNTech in collaboration with the US-based Pfizer announced that 12 participants of a clinical trial in Germany received doses of the vaccine candidate BNT162 since April 23, reported Al Jazeera.

They said in an announcement on Wednesday that, in the next step, it will begin increasing the dose of BNT162 in a trial involving about 200 participants aged 18 to 55.

The company is expecting to receive regulatory approval to begin trials in the United States soon.

Meanwhile, numerous pharmaceutical companies are racing to deliver a vaccine to impede the virus from spreading further which has caused more than 215,000 deaths worldwide and sickened at least three million people.

While a safe, effective vaccine is still more than a year away, researchers are rushing to repurpose existing drugs and non-drug therapies as well as testing promising experimental drugs that were already in clinical trials.

New drugs with support of new diagnostics, antibody tests, patient- and contact-tracing technologies, disease surveillance and other early-warning tools - indicate that the world will be cautiously prepared for the next pandemic, unlike this one.

As many as 100 potential COVID-19 candidate vaccines are now under development by biotech and research teams around the world, and at least five of these have gone into phase-1 of their clinical trial, known as preliminary human trials.

Scientists in the United Kingdom began clinical trials of a potential COVID-19 vaccine on April 23 as other vaccine developers across Europe stepped up work on experimental shots.

The team at the UK's Oxford University dosed the first volunteers in a trial of their vaccine - called "ChAdOx1 nCoV-19" - while Italy's ReiThera, Germany's Leukocare and Belgium's Univercells said they were working together on another potential shot and aimed to start trials in a few months.

The UK's GSK and France's Sanofi have announced a similar agreement to develop a COVID-19 vaccine, with trials starting in the second half of the year.

Top News

Vaccine / german / human trial

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Corporates go cashless…tax cut on cards
    Corporates go cashless…tax cut on cards
  • Rising revenue collection a false dawn, economists say
    Rising revenue collection a false dawn, economists say
  • Why we must resist geoeconomic fragmentation—and how
    Why we must resist geoeconomic fragmentation—and how

MOST VIEWED

  • A medical worker takes a swab sample from a person for a nucleic acid test at a makeshift testing site, amid the coronavirus disease (Covid-19) outbreak, in Beijing, China May 23, 2022. REUTERS/Tingshu Wang
    Beijing urges millions to keep working from home amid Covid outbreak menace
  • Picture: PTI
    Saudi Arabia bans travel to India, 15 other countries over Covid outbreaks
  • A person in personal protective equipment (PPE) walks a dog at a resident community, as the second stage of a two-stage lockdown has been launched to curb the spread of the coronavirus disease (Covid-19) in Shanghai, China April 3, 2022. REUTERS/Aly Song
    Shanghai reopens some public transport, still on high Covid alert
  • Workers in protective suit spray disinfectant at a community, during the lockdown to curb the spread of the coronavirus disease (COVID-19) in Shanghai, China, April 5, 2022. REUTERS/Aly Song
    Dynamic zero-Covid approach: China's choice to safeguard lives, underpin growth
  • People wearing protective face masks walk on a street, following new cases of the coronavirus disease (Covid-19), in Shanghai, China August 25, 2021. REUTERS/Aly Song
    Shanghai district to require all shops to shut, residents to stay home
  • Photo: Courtesy
    Covax calls for urgent action to close vaccine equity gap

Related News

  • Covax calls for urgent action to close vaccine equity gap
  • Over 700,000 refugees from Ukraine registered in Germany -Welt
  • Cholera inoculation in Dhaka starting first week of May
  • Corruption allegation over vaccine has no evidence: Ahmad Kaikaus
  • 23 lakh citizens to get cholera vaccine in Dhaka from May

Features

Musk is denying the sexual harassment allegation that surfaced this week. Photo: Bloomberg

Elon Musk’s crazily banal week 

17h | Panorama
Asus Zenbook 14 Flip OLED: A touch of brilliance to your life

Asus Zenbook 14 Flip OLED: A touch of brilliance to your life

21h | Brands
Keep your phone by your side with this armband

Keep your phone by your side with this armband

18h | Brands
Are Focallure gel masks worth the hype?

Are Focallure gel masks worth the hype?

19h | Brands

More Videos from TBS

Why are Duranta TV shows popular?

Why are Duranta TV shows popular?

13h | Videos
Donbas is hell, says Zelenskiy

Donbas is hell, says Zelenskiy

14h | Videos
Threat of Monkeypox on the horizon

Threat of Monkeypox on the horizon

14h | Videos
Mosque of Mughal period in Gazipur

Mosque of Mughal period in Gazipur

15h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

3
Bangladesh at risk of losing ownership of Banglar Samriddhi
Bangladesh

Bangladesh at risk of losing ownership of Banglar Samriddhi

4
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

5
BSEC launches probe against Abul Khayer Hero and allies
Stocks

BSEC launches probe against Abul Khayer Hero and allies

6
The reception is a volumetric box-shaped room that has two glass walls on both the front and back ends and the other two walls are adorned with interior plants, wood and aluminium screens. Photo: Noor-A-Alam
Habitat

The United House: Living and working inside nature

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab